Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2021 March Pharma News Flumatinib induces higher rates of deep responses compared to imatinib in CML Read more
2021 March Clinical practice Validation of the revised 2017 European LeukemiaNet genetic risk stratification for AML Read more
Top
